核糖核酸降低食管癌患者放疗期间 呕吐等不良反应的疗效观察

Clinical application of ribonucleic acid in esophageal cancer patients receiving radiotherapy

摘要:

目的 观察注射用核糖核酸Ⅱ对食管癌患者放射治疗（放疗）期间呕吐等不良反应的临床效果和安 全性。方法 选取2014 年5 月—2017 年1 月江苏省肿瘤医院放疗科收治的食管癌患者76 例，随机分为对照组与 观察组。对照组只接受放疗；观察组在接受放疗的同时应用注射用核糖核酸Ⅱ辅助治疗。比较两组治疗前后呕 吐等不良反应、药物不良反应发生情况及免疫力。结果 与对照组比较，观察组呕吐和放射性食管炎发生率降 低（P <0.05）；观察组放疗总有效率（81.6%）较对照组（55.3%）提高（P <0.05），红细胞、白细胞及血小板数 量升高（P <0.05）；血清中CD3+、CD4+ 水平和CD4+/CD8+ 升高（P <0.05），而头晕发生率降低（P <0.05）。结 论 注射用核糖核酸Ⅱ具有降低食管癌放疗患者呕吐等副反应、保护血细胞及提高免疫力的作用，还能增强放 疗效果。

Abstract:

Objective To observe the clinical efficacy and safety of ribonucleic acid II in esophageal cancer patients receiving radiotherapy. Methods Totally 76 cases of esophageal cancer admitted into our hospital from May 2014 to January 2017 were involved and randomly divided into control group and observation group. All patients received standard radiation therapy. Patients in observation group received additional ribonucleic acid II at the same time. Radiotherapy induced vomiting, drug related adverse reactions and immune index were recorded. Results Incidence of vomiting, dizziness, and radiation esophagitis decreased significantly in observation group compared with control group (P < 0.05). The total effective rate of radiotherapy was elevated in observation group when compared with control group (81.6% vs 55.3%, P < 0.05). The number of red blood cells, white blood cells and platelets, the level of CD3+, CD4+, and CD4+/CD8+ in peripheral blood was upregulated significantly in observation group compared with those in control group (P < 0.01). Conclusions Ribonucleic acid II reduces radiotherapy induced vomit, maintains immunity and enhances efficacy of radiotherapy.